SBIR Phase I: A Method to Prevent Dilation of the Heart Following an Acute Myocardial Infarction.

这个小企业创新研究（SBIR）第一阶段项目旨在开发一种设备，以防止心脏病发作后患者的充血性心力衰竭（CHF）。目前还没有有效的方法来预防CHF的发展。几种放置在心脏周围的被动约束装置已显示对已确诊的CHF患者有益。最近的动物研究表明，在心脏病发作后立即放置这些装置可以预防心力衰竭。然而，由于其持久性，它们只能用于已确诊的CHF患者。这项研究继续开发并进行了一种设备的初步动物试验，以防止心脏病发作后患者进展为CHF。这个项目更广泛的影响将是减少瑞士法郎，这是一种影响550万美国人的疾病，每年花费医疗系统300亿美元。心脏病发作是导致心力衰竭的主要原因，它使心脏承受巨大的机械压力，从而导致心力衰竭。在美国，每年大约有120万患者心脏病发作。目前，只有少数医疗策略可以减缓进展到CHF，没有真正的方法来预防它。这项技术开发了一种微创生物可降解装置，以延缓或防止患者在心脏病发作后发展为CHF。该设备将提供一种急需的基于设备的治疗，有可能从根本上改变目前的治疗模式，估计每年的市场潜力为30亿美元。

This Small Business Innovation Research (SBIR) Phase 1 project aims to develop a device to prevent congestive heart failure (CHF) in patients after a heart attack. There is currently no effective way to prevent the development of CHF. Several passive restraint devices placed around the heart have shown benefit in patients with established CHF. Recent animal studies have shown that these devices can prevent CHF when placed immediately after a heart attack. However, due to their permanence, they can only be used in patients with established CHF. This research continues the development and performs initial animal testing of a device to prevent progression to CHF in patients after a heart attack. The broader impact of this project will be to reduce CHF is, which is a disease that affects 5.5 million Americans costing the healthcare system $30 billion a year. Heart attacks, the leading cause of CHF, place the heart under significant mechanical stresses leading to CHF. Every year, almost 1.2 million patients suffer from a heart attack in the United States. Currently, there are only a few medical strategies to slow down progression to CHF and no real way to prevent it. This technology develops a minimally invasive biodegradable device to delay or prevent patients from developing CHF after a heart attack. This device will provide a much needed device based therapy, potentially radically modifying current treatment paradigms with an estimated annual market potential of $3 billion.